Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenishaw Regulatory News (RSW)

Share Price Information for Renishaw (RSW)

Share Price is delayed by 15 minutes
Get Live Data
5,390.00    -65.00 (-1.19%)
Bid:
5,410.00
Ask:
5,420.00
Spread: 10.00 (0.185%)
Market Cap: £3.92b
RSW Live PriceLast checked at - London Stock Exchange

Intraday Renishaw Share Chart

Trading Statement

24 Oct 2024 07:00

RNS Number : 3723J
Renishaw PLC
24 October 2024
 

Renishaw plc

Trading update

24 October 2024

 

 

Solid revenue and profit growth in mixed trading conditions

Renishaw plc, the global provider of manufacturing technologies, analytical instruments and medical devices, publishes this trading update for the three months ended 30 September 2024. It contains unaudited information that covers the first quarter of the financial year.

 

 

Trading activity

 

 

3 months to 30 September 2024

3 months to 30 September 2023

Change

 

 

 

 

Manufacturing technologies

£167.5m

£156.8m

+7%

Analytical instruments and medical devices

£6.4m

£7.7m

-16%

Total revenue

£173.9m

£164.5m

+6%

Total revenue at constant exchange rates1

£171.3m

£165.0m

+4%

 

 

 

Adjusted profit before tax2

£34.0m

£28.0m

+22%

Statutory profit before tax

£34.0m

£28.0m

+22%

 

 

Revenue was £173.9m, representing a 6% increase compared to the corresponding period last year at actual exchange rates, and a 4% increase at constant currency1. The Americas and EMEA regions saw increased demand compared to Q1 FY2024, whilst APAC was lower compared to a strong period last year, which was boosted by orders from the consumer electronics sector. 

 

In our Manufacturing technologies business, revenue in the period was 7% higher than the prior year at £167.5m. Sales of position encoders to the semiconductor manufacturing sector saw strong growth compared to a subdued prior year comparator. Our Additive Manufacturing products also grew strongly, reflecting the good order book carried into FY2025. Meanwhile, demand for Industrial Metrology products was lower than last year, primarily due to the strong prior period sales to consumer electronics manufacturers in APAC.

 

Revenue for our Analytical instruments and medical devices business was £6.4m, a decrease of 16% compared with £7.7m last year, primarily from phasing for our Spectroscopy products.

 

Adjusted and Statutory profit before tax2 for the first quarter of FY2025 both amounted to £34.0m (FY2024: £28.0m).

 

 

Financial position

 

The Group's balance sheet remains strong with net cash and cash equivalents and bank deposit balances of £276.1m on 30 September 2024 (30 June 2024: £217.8m).

 

 

Outlook

 

The first quarter of FY2025 has seen solid revenue and profit growth in mixed trading conditions, with subdued demand in some markets, offset by good growth elsewhere. Whilst Q1 sales of our encoder products to the semiconductor manufacturing sector have been stronger than last year, we remain cautious about demand from this market in the remainder of FY2025. 

 

We continue to pursue a range of growth opportunities and anticipate solid overall revenue growth this year in line with the Board's expectations. Alongside this we also remain focused on the careful management of costs and delivery of productivity improvements, which together will help drive progress towards our margin objectives.

The results for the half year ending 31 December 2024 will be released on 13 February 2025.

 

Will Lee

Allen Roberts

 

Chief Executive

Group Finance Director

 

 

24 October 2024

 

 

Renishaw plc

Registered office

New Mills, Wotton-under-Edge, Gloucestershire, GL12 8JR

Registered number

01106260

Telephone number

+44 (0) 1453 524524

Website

www.renishaw.com

 

 

 

Notes

 

1. Revenue at constant exchange rates is defined as revenue recalculated using the same rates that were applicable to the previous year and excluding forward contract gains and losses.

2. There are no adjustments made between statutory and adjusted profit before tax.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAKEDALELFFA
Date   Source Headline
25th Apr 201212:48 pmRNSDirectorate Change
16th Apr 20122:08 pmRNSDirector/PDMR Shareholding
25th Jan 20127:00 amRNSHalf Yearly Report
12th Dec 20111:44 pmRNSHolding(s) in Company
24th Oct 20118:17 amRNSDirector/PDMR Shareholding
13th Oct 20112:19 pmRNSResult of AGM
13th Oct 201111:26 amRNSHolding(s) in Company
13th Oct 201111:05 amRNSInterim Management Statement
7th Sep 20113:56 pmRNSAnnual Information Update
19th Aug 20118:56 amRNSAnnual Financial Report
12th Aug 20119:02 amRNSDirector/PDMR Shareholding
27th Jun 20111:30 pmRNSFacilities expansion plans
23rd Jun 201112:09 pmRNSHolding(s) in Company
17th May 20117:00 amRNSInterim Management Statement
26th Apr 20119:53 amRNSDirector/PDMR Shareholding
16th Mar 20113:17 pmRNSHolding(s) in Company
26th Jan 20117:00 amRNSHalf Yearly Report
24th Dec 20109:35 amRNSDirector/PDMR Shareholding
14th Oct 20102:29 pmRNSResult of AGM
14th Oct 201010:37 amRNSInterim Management Statement
9th Sep 20107:00 amRNSTrading Statement
1st Sep 20101:15 pmRNSAnnual Information Update
23rd Aug 20107:00 amRNSAnnual Financial Report
28th Jul 20107:00 amRNSFinal Results
23rd Jun 20101:51 pmRNSHolding(s) in Company - Replacement
23rd Jun 20101:50 pmRNSHolding(s) in Company - Replacement
23rd Jun 20101:43 pmRNSDirector/PDMR Shareholding
23rd Jun 20101:39 pmRNSDirector/PDMR Shareholding - Replacement
22nd Jun 201011:52 amRNSHolding(s) in Company
22nd Jun 201011:51 amRNSHolding(s) in Company
22nd Jun 201011:49 amRNSDirector/PDMR Shareholding
22nd Jun 201011:46 amRNSDirector/PDMR Shareholding
21st Jun 20105:32 pmRNSHolding(s) in Company
21st Jun 20105:23 pmRNSDirector/PDMR Shareholding
17th May 20109:32 amRNSDirector/PDMR Shareholding
14th May 20107:00 amRNSInterim Management Statement
23rd Apr 201011:50 amRNSDirector/PDMR Shareholding
23rd Apr 201011:03 amRNSDirector/PDMR Shareholding
27th Jan 201012:28 pmRNSHalf Yearly Report - Replacement
27th Jan 20107:30 amRNSHalf Yearly Report
19th Jan 20108:06 amRNSHolding(s) in Company
7th Dec 20097:00 amRNSTrading Statement
26th Nov 20099:49 amRNSDirector Declaration
15th Oct 20092:25 pmRNSResult of AGM
15th Oct 200911:06 amRNSInterim Management Statement
29th Sep 20097:30 amRNSTrading Statement
24th Aug 20098:51 amRNSAnnual Financial Report
29th Jul 20097:30 amRNSFinal Results
6th Jul 20097:44 amRNSCompany Secretary Change
26th May 200912:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.